The Implications of Cost-effectiveness Analysis of Medical TechnologyCongress of the United States, Office of Technology Assessment, 1980 - 219 pages |
From inside the book
Results 1-5 of 37
Page 8
... responsibility for identifying questions about whether a tech- nology should be covered lies with a system of local contractors who administer the program . When not resolved at the local level , a question is referred to the Health ...
... responsibility for identifying questions about whether a tech- nology should be covered lies with a system of local contractors who administer the program . When not resolved at the local level , a question is referred to the Health ...
Page 29
... responsibility of weighing the consequences of decisions . Since CEA / CBA is being spoken of or advo- cated as a mechanism to assist policymakers in making rational choices between competing ob- jectives , OTA was asked to assess the ...
... responsibility of weighing the consequences of decisions . Since CEA / CBA is being spoken of or advo- cated as a mechanism to assist policymakers in making rational choices between competing ob- jectives , OTA was asked to assess the ...
Page 42
... responsibility SOURCE : Office of Technology Assessment . Widespread Nonuse Financing NIH FDA NCHCT NCHSR HCFA HSAS PSROS Obsolescence 5 . Reimbursement Medicare and Blue Cross / Blue Shield 42 • The Implications of Cost - Effectiveness ...
... responsibility SOURCE : Office of Technology Assessment . Widespread Nonuse Financing NIH FDA NCHCT NCHSR HCFA HSAS PSROS Obsolescence 5 . Reimbursement Medicare and Blue Cross / Blue Shield 42 • The Implications of Cost - Effectiveness ...
Page 43
... responsibility Conduct research on quality of medical care through medical care evaluation studies and profile analyses ... responsible for providing the community or regionally based HSAs with technical assistance and guidance regarding ...
... responsibility Conduct research on quality of medical care through medical care evaluation studies and profile analyses ... responsible for providing the community or regionally based HSAs with technical assistance and guidance regarding ...
Page 47
... administer part A , fiscal intermediaries , and part B , carriers , of medicare bear the ini- tial responsibility for identifying coverage issues and determining reimbursement policy.3 Through the advice provided by 47 Reimbursement.
... administer part A , fiscal intermediaries , and part B , carriers , of medicare bear the ini- tial responsibility for identifying coverage issues and determining reimbursement policy.3 Through the advice provided by 47 Reimbursement.
Other editions - View all
Common terms and phrases
Administration advisory agencies application areas assessment Background Paper biomedical Blue Shield budget Cancer CEA and CBA CEA or CBA CEA/CBA clinical trials conducted considerations Cost of Illness Cost-Benefit Analysis cost-benefit studies cost-effectiveness costs and benefits coverage criteria deci decisionmaking DHHS disease economic economists effectiveness enrollees evaluation example FDA's Federal formal CEA/CBA funding goals gram HCFA Health Care Technology Health Maintenance Organizations health planning health services research hospital HSAs identified impact individual Institute issues measure medical devices medical technologies medicare ment methodological Mishan National NCHCT NCHSR nomic Office option organizations outcomes panel peer review performance physicians policymakers potential priority problem procedures PSRO Public Law quality-adjusted reimbursement safety and efficacy scientific sions social specific staff standards tech techniques tion tive treatment types U.S. Congress
Popular passages
Page 88 - As used in this subsection and subsection (e), the term "substantial evidence" means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is presented to have under the conditions of use prescribed, recommended,...
Page 48 - A), the National Institutes of Health (NIH), and the Food and Drug Administration (FDA).
Page 88 - Administration with respect to such drug, there is lack of substantial evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested...
Page 62 - ... (B) the quality of such services meets professionally recognized standards of health care ; and (C) in case such services and items are proposed to be provided in a hospital or other health care facility on an inpatient basis, such services and items could, consistent with the provision of appropriate medical care, be effectively provided on an outpatient basis or more economically in an inpatient health care facility of a different type.
Page 191 - Risk: A measure of the probability of an adverse or untoward outcome and the severity of the resultant harm to health of individuals in a defined population associated with use of a medical technology applied for a given medical problem under specified conditions of use.
Page 47 - Notwithstanding any other provision of this title, no payment may be made under part A or part B for any expenses incurred for items or services — (/) which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member...
Page 52 - Nothing in this title shall be construed to authorize any Federal officer or employee to exercise any supervision or control over the practice of medicine or the manner in which medical services are provided...
Page 3 - Medical technology: The drugs, devices, and medical and surgical procedures used in medical care, and the organizational and supportive systems within which such care is provided.
Page 190 - Effectiveness: Same as efficacy (see below) except that it refers to average or actual conditions of use. Efficacy: The probability of benefit to individuals in a defined population from a medical technology applied for a given medical problem under ideal conditions of use.
Page 182 - First, cost-benefit analysis as generally understood is only a technique for taking decisions within a framework which has to be decided upon in advance and which involves a wide range of considerations, many of them of a political or social character.